The company has a potential life-saving catalyst in its portfolio, too.
There's no compelling reason to buy this stock above $40.
The market seems divided on where the company is heading next.
Stryker needs a new set of offerings that allows it to differentiate from peers that are trading at a much lower multiple.
With Red Hat's long history of open source expertise, the company is in position to dominate its market for years to come.
With the recent deal for DAVA, Endo is now one of the best health care stocks to own.
Investors only need to sit back and let management work its magic.
Best Buy does have some risks, but the potential rewards are too great to ignore.
Like a smart shopper, wait for the stock to go pull back to the mid-$40s and buy.
It will only take one bad quarter for shares to fall to single digits. That's the only time you should buy.